EpicentRx Beta-Prime: Solid Tumors

A BETA-PRIME: A Phase I Study to evaluate the safety and tolerability of AdAPT-001 in subjects with Refractory Solid Tumors who have been previously treated with standard lines of therapy and their disease has progressed on other treatment or there are no appropriate therapies available for their cancer.